Shares of International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.15 and traded as high as $0.17. International Stem Cell shares last traded at $0.17, with a volume of 174 shares.
International Stem Cell Stock Down 3.8%
The business’s fifty day simple moving average is $0.16 and its two-hundred day simple moving average is $0.15. The company has a market cap of $1.36 million, a price-to-earnings ratio of -2.83 and a beta of 0.06.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share for the quarter. The business had revenue of $2.32 million for the quarter.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
See Also
- Five stocks we like better than International Stem Cell
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
